In order to promote the research of anti-novel coronavirus drugs and vaccines, Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd. has made great efforts to establish sophisticated technical systems in line with international and domestic GLP standards to promote novel coronavirus vaccines and drugs research and development.

 

Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd. (briefed as Lewwin PRI) is a leading technical systems R&D and service CRO company in line with GLP standards. Lewwin PRI has a strong leadership management team and technical expert teams with complimentary expertise. It composes of:

§  Academicians of the Chinese Academy of Sciences,

§  Experts of National New Drug Evaluation,

§  High-level talents in Guangzhou,

§  Leading talents in Guangdong Province and

§  Leading talents in Guangdong Academy of Sciences.

 

Lewwin is the first (presently the only one) non-clinical drug evaluation and research platform in South China.  The Lewwin Research Institute (PRI) has nine full GLP certification qualifications of the National Medical Products Administration of China, and has been fully certified by the International AAALAC in a variety of animals and multi-business areas. Currently, it has established a number of technical platforms; including:

§  Guangdong Provincial Key Laboratory of Drug Non-clinical Evaluation and Research,

§  Non-clinical Evaluation Sub-center for Traditional Chinese Medicine of National Engineering Research Center for Modernization of Traditional Chinese Medicine,

§  Guangdong Engineering Research Center for Innovative Drug Evaluation and Research, and

§  Guangdong Provincial Center for Ophthalmic Drug Creation and Evaluation Engineering Technology (South China Ophthalmic Medicine Comprehensive Creation Platform),

§  Guangdong Engineering Research Center for Cellular and Genetic Therapy Innovative Drugs, and

§  National Joint Engineering Research Center for Ultrafine Granular Powder of Chinese Materia Medica. 

 

The research institute has strong technical developmental capabilities and advantages especially in cells and genes drug detection platforms. Additionally, advanced detection technologies such as:

§  Hypersensitive multi-factor electrochemiluminescence detection platform,

§  Flow cell?? detection platform,

§  Molecular imaging technology platform,

§  Enzyme-linked immunosorbent detection platform

§  Nucleic acid fluorescence quantitative detection technology,

 

And our technological abilities are continuously growing and are home to more than 600 standard instruments and equipment.  The institute is also equipped with:

§  Hypersensitive multi-factor electrochemiluminescence analyzer (MSD S600),

§  Beckman flow cytometry CytoFLEX,

§  Real-time fluorescence quantitative PCR Light Cycler 480, f

§  Fluorescence full-wavelength multi-function enzyme marker Synergy LX,

§  Small animal in vivo imaging system IVIS Lumina LT,

§  Gene amplification instrument Life-Eco,

§  Gel imaging system Gel Doc XR+,

§  Vertical electrophoresis tank Mini-proteam Tetra,

§  Nucleic acid electrophoresis tank Wide Mini Sub-Cell GT,

§  Digital display voltage-stabilized current electrophoresis instrument PowerPac HC,

§  Molecular biology research equipment such as Trans-Blot SD Semidry, inverted fluorescence microscope TCM 400, Allegra ®X Mel 5 desktop centrifuge, and aN Optima MAX-XP desktop ultracentrifuge,

§  Series of ultra-high performance liquid chromatography-mass spectrometry (LC/MS,), including XEVO TQD, XEVO TQS, H-Class Plus/XEVO TQD, Vion IMS QTof ion mobility analysis mass spectrometer and other analysis equipment. 

§  As well as other instruments catering to a wide variety of scientific needs.

 

 

In accordance with the requirements of GLP domestically and abroad, the Lewwin Research Institute has successfully evaluated and supported the clinical approval of multiple genes and therapeutic drugs and provided strong support for the establishment of non-clinical evaluation research system of new vaccines.  Together, it organically integrates resources with Wuhan Topgene Biotechnology Co., Ltd and Harbin Veterinary Research Institute, CAAS (P4, and approved by the National Health Commission to study new coronavirus) to solve the bottleneck of non-clinical evaluation of a new coronavirus vaccine in an one-stop way from non-human primate resources, challenge tests and GLP safety evaluation to international AAALAC requirements.  We can fully cooperate together to solve the shortage of resources for vaccine R & D and evaluation and make a tremendous effort to improve the speed of novel coronavirus's vaccine, drug research and development!

 

Contact person:

Jianmin GUO, PhD and Senior Engineer in Pharmaceutical

 Deputy General Manager of Lewwin Pharmaceutical Research Institute Co., Ltd

Tel: (011-86)-18028620702

Fax: (011-86)-20-22698383

Wechat: 18028620702

Email: guojianmin@lewwin.com.cn

 

CEO:

Wei YANG, Visiting Professor of pharmacology, Doctorial Supervisor

Professorate Senior Engineer in Pharmaceutical

Chairman of Board of Directors and General Manager of Lewwin Pharmaceutical Research Institute Co., Ltd

Tel: (011-86)-18928860179

Fax: (011-86)-20-22698383

Wechat: 18928860179

Email: yangwei0719@163.com

 

 

Novel coronavirus (SARS-CoV-2) vaccine development related detection technology has been established.